Pharma BD Deal Intelligence
Bristol-Myers Squibb Company / BioArctic AB
2024 · Licensing/Option · $1.4B · Complete
Announcement Sentiment
67
Positive
Outcome Score
65
Largely worked — most objectives met.
BMS licensed BioArctic's anti-amyloid antibodies BAN1503 and BAN2803 for Alzheimer's disease development and commercialization.
Key facts
- Announced Dec 19, 2024
- Closed Feb 20, 2025
- Deal value $1.4B
- Deal type Licensing/Option
- Therapeutic area Neurology
- Indications Alzheimer's disease
- Key assets BAN1503, BAN2803
- Mechanism Anti-amyloid beta antibody
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals